Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway

BACKGROUND: The sustained clinical activity of the BRAF inhibitor vemurafenib (PLX4032/RG7204) in patients with BRAF(V600) mutant melanoma is limited primarily by the development of acquired resistance leading to tumor progression. Clinical trials are in progress using MEK inhibitors following disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Atefi, Mohammad, von Euw, Erika, Attar, Narsis, Ng, Charles, Chu, Connie, Guo, Deliang, Nazarian, Ramin, Chmielowski, Bartosz, Glaspy, John A., Comin-Anduix, Begonya, Mischel, Paul S., Lo, Roger S., Ribas, Antoni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3237573/
https://www.ncbi.nlm.nih.gov/pubmed/22194965
http://dx.doi.org/10.1371/journal.pone.0028973

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3237573/
https://www.ncbi.nlm.nih.gov/pubmed/22194965
http://dx.doi.org/10.1371/journal.pone.0028973

Ejemplares similares